![](https://jannelab.org/sites/default/files/styles/staff_photo/public/Mustafa%20Photo%202022%20Cropped.jpg?itok=5rJvnFsP)
Mustafa Al-Dulaimi, BS, (mustafa_al-dulaimi@dfci.harvard.edu) works on investigating the impact of different combinations of RTKi treatments with the goal of overcoming and preventing acquired resistance to EGFR-targeted therapies in EGFR-mutant NSCLC. He also works on identifying targeted therapy options for mesotheliomas by researching potential therapeutic vulnerabilities.
![](https://jannelab.org/sites/default/files/styles/staff_photo/public/Lishu%20Liao%20portrait%20cropped.jpg?itok=MiMQt1BV)
Lishu Liao, BS, (lishu_liao@dfci.harvard.edu) mainly works on EGFR-mutant NSCLC cell lines with the focus of finding targetable vulnerabilities for EGFR-TKI resistant cells based on genes/pathways involved in DNA damage repair and cell cycle regulation. She is also responsible for establishing in vitro 2D & 3D cell line models of NSCLC from both PDX and patient pleural effusion samples.
![](https://jannelab.org/sites/default/files/styles/staff_photo/public/PhotoJoeKulesza%281%29.jpg?itok=jBnPsjMx)
Joe Kulesza, BA, (joseph_kulesza@dfci.harvard.edu) work involves understanding how non-small cell lung cancers develop resistance to targeted therapy. His current projects focus on the nuclear transcription factor AP-1 and the chromatin remodeling complex BAF.
![Portrait of Felix Gottlieb](https://jannelab.org/sites/default/files/styles/staff_photo/public/Felix%20Portrait%20Cropped.jpg?itok=2XhfU3nn)
Felix Gottlieb, BS, (felix_gottlieb@dfci.harvard.edu) works on identifying patterns of MET dysregulation as de novo oncogenic drivers in NSCLC. He also investigates MET dysregulation in the context of other oncogene-driven lung tumors, such as EGFR and KRAS, as well as novel targeted therapies for overcoming these resistance mechanisms.